NASDAQ:ADMP Adamis Pharmaceuticals (ADMP) Stock Forecast, Price & News $0.78 +0.01 (+0.86%) (As of 09/7/2023) Add Compare Share Share Today's Range$0.75▼$0.7950-Day Range$0.77▼$3.9952-Week Range$0.75▼$26.18Volume119,800 shsAverage Volume811,695 shsMarket Capitalization$7.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Adamis Pharmaceuticals (NASDAQ:ADMP) StockAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Read More ADMP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMP Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Earns Sell Rating from Analysts at StockNews.comSeptember 19, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)September 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 7, 2023 | msn.comAdamis changes name to DMK Pharmaceuticals, ticker to DMKSeptember 7, 2023 | finance.yahoo.comAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic FocusAugust 21, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 21, 2023 | finance.yahoo.comAdamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 4, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 2, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Pricing of $8.0 Million Public OfferingAugust 1, 2023 | msn.comAdamis Pharmaceuticals Stock Soars To More Than Double - What's Going On?August 1, 2023 | msn.comAdamis stock soars as high as 480% amid asset sale, drug study newsJuly 28, 2023 | marketwatch.comAdamis Pharma to Fund Clinical Study with University of Leiden Opioid ExpertJuly 28, 2023 | finance.yahoo.comAdamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid ExpertJune 26, 2023 | benzinga.comAdamis Pharmaceuticals Announces NIH Grant Funding For Treatment Of Alcohol Use Disorder, Size Not DisclosedJune 26, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use DisorderJune 22, 2023 | finance.yahoo.comAdamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose PreventionJune 4, 2023 | fool.comAdamis Pharmaceuticals (NASDAQ: ADMP)May 31, 2023 | benzinga.comAdamis Pharmaceuticals CEO Awarded $210K Worth of Stock OptionsMay 31, 2023 | benzinga.comBoard Member at Adamis Pharmaceuticals Acquires Company Stock Options Worth 25,720 SharesMay 26, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsMay 25, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsMay 21, 2023 | seekingalpha.comAdamis Pharma slips 19% on plans for reverse stock slipMay 19, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Reverse Stock SplitMay 19, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Reverse Stock SplitMay 16, 2023 | finance.yahoo.comQ1 2023 Adamis Pharmaceuticals Corp Earnings CallMay 15, 2023 | finance.yahoo.comAdamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive ADMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMP Company Calendar Last Earnings3/31/2022Today9/26/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMP CUSIPN/A CIK887247 Webwww.adamispharmaceuticals.com Phone(858) 997-2400FaxN/AEmployees11Year Founded2006Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-502.73% Pretax Margin-471.80% Return on Equity-420.53% Return on Assets-256.87% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.19 Sales & Book Value Annual Sales$4.76 million Price / Sales1.52 Cash FlowN/A Price / Cash FlowN/A Book Value($1.26) per share Price / Book-0.62Miscellaneous Outstanding Shares9,360,000Free Float9,237,000Market Cap$7.25 million OptionableOptionable Beta1.27 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David J. Marguglio (Age 53)Co-Founder, Interim CFO. Pres & COO Comp: $526.35kDr. Ebrahim Versi M.D. (Age 70)Ph.D., CEO & Chair of the Board Ms. Jennifer C. SuskiSr. Director of MarketingMr. Eddie Wabern Glover (Age 73)Chief Exec. Officer of US Compounding Inc Mr. Robert B. Rothermel (Age 79)Consultant Key CompetitorsTenax TherapeuticsNASDAQ:TENXLexaria BioscienceNASDAQ:LEXXBiodexa PharmaceuticalsNASDAQ:BDRXAileron TherapeuticsNASDAQ:ALRNCervoMedNASDAQ:CRVOView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 4,200 shares on 8/15/2023Ownership: 0.000%BlackRock Inc.Sold 2,727,409 shares on 8/11/2023Ownership: 1.417%Geode Capital Management LLCSold 1,307,707 shares on 8/11/2023Ownership: 0.679%Simplex Trading LLCSold 2,700 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions ADMP Stock - Frequently Asked Questions How have ADMP shares performed in 2023? Adamis Pharmaceuticals' stock was trading at $11.8510 on January 1st, 2023. Since then, ADMP shares have decreased by 93.5% and is now trading at $0.7751. View the best growth stocks for 2023 here. When is Adamis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ADMP earnings forecast. How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its quarterly earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%. During the same quarter in the prior year, the company posted ($11.20) EPS. When did Adamis Pharmaceuticals' stock split? Adamis Pharmaceuticals's stock reverse split on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK). What is Adamis Pharmaceuticals' stock symbol? Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP." Who are Adamis Pharmaceuticals' major shareholders? Adamis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.42%), Geode Capital Management LLC (0.68%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David C Benedicto, David J Marguglio, Dennis J Phd Carlo, Robert O Hopkins and Ronald B Moss. View institutional ownership trends. How do I buy shares of Adamis Pharmaceuticals? Shares of ADMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adamis Pharmaceuticals' stock price today? One share of ADMP stock can currently be purchased for approximately $0.78. How much money does Adamis Pharmaceuticals make? Adamis Pharmaceuticals (NASDAQ:ADMP) has a market capitalization of $7.25 million and generates $4.76 million in revenue each year. How can I contact Adamis Pharmaceuticals? Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.adamispharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at mflather@adamispharma.com. This page (NASDAQ:ADMP) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamis Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.